Last reviewed · How we verify
Tazarotene Foam
Tazarotene Foam is a topical retinoid that modulates cell growth and differentiation.
Tazarotene Foam is a topical retinoid that modulates cell growth and differentiation. Used for Acne vulgaris, Fine wrinkles.
At a glance
| Generic name | Tazarotene Foam |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Drug class | retinoid |
| Target | retinoic acid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to retinoic acid receptors, which are involved in regulating cell growth and differentiation. This leads to a decrease in the thickness of the skin and an improvement in the appearance of acne and fine wrinkles.
Approved indications
- Acne vulgaris
- Fine wrinkles
Common side effects
- Skin irritation
- Dry skin
- Redness
Key clinical trials
- A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris (PHASE3)
- A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris (PHASE1)
- A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers (PHASE1)
- A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers (PHASE1)
- A Study To Evaluate The Contact Sensitization Potential Of Tazarotene Foam On Skin In Healthy Volunteers (PHASE1)
- A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers. (PHASE1)
- A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne (PHASE3)
- A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene Foam CI brief — competitive landscape report
- Tazarotene Foam updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI